Associated Papers
CNL and aCML should be considered as a single entity based on molecular profiles and outcomes.
Carreño-Tarragona G et al.
Blood Advances, 2023
36375042 (PubMed )
Supplement: BLOODA_ADV-2022-008204-mmc1.pdf
Disease evolution and outcomes in familial AML with germline CEBPA mutations.
Tawana K et al.
Blood, 2015
Select a paper to view details